Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT04815668Recruiting
Acupuncture for moderate-to-severe seasonal allergy rhinitis
This trial tests whether acupuncture at a specific spot behind the nose can reduce symptoms from seasonal allergies (triggered by things like grass or birch pollen). It may help if your allergy symptoms are moderate to severe and have lasted for a long time.
BeijingAges 18–75 - NCT06807268RecruitingPhase 3
A study of abrocitinib for children ages 6–11 with eczema
This trial tests a daily pill called Abrocitinib to see if it can help children ages 6 to 11 with moderate-to-severe eczema that hasn't gotten better with creams or ointments. Eczema (also called atopic dermatitis) causes itchy, red skin, and this medicine might calm the immune response to reduce itching and rashes.
Birmingham, AlabamaAges 6–11 - NCT06807281RecruitingPhase 3
Abrocitinib for children with eczema: long-term study
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
Birmingham, AlabamaAges 2–11 - NCT06805175Recruiting
Balance implant study for adults with dizziness
This study tests a new device that may help restore balance for people with long-term dizziness from inner ear problems. The implant is placed surgically to stimulate the balance nerve.
Antwerp, WilrijkAges 18 years+ - NCT06775860RecruitingPhase 3
Testing ICP-332 for moderate to severe eczema
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hefei, AnhuiAges 18–75 - NCT06764706Recruiting
Risankizumab for moderate-to-severe ulcerative colitis
This study observes how well risankizumab works for people with moderate to severe ulcerative colitis who are already starting it as part of their regular care. It helps doctors learn more about the drug's real-world effects.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06761560RecruitingPhase 2/Phase 3
Hydroxyurea dosing for children with sickle cell anemia
This study looks at whether adjusting the dose of hydroxyurea based on drug levels in the blood works better than the standard approach for treating sickle cell disease in children. It aims to reduce side effects and improve treatment outcomes.
Montreal, QuebecAges 6 months–18 years - NCT06752759RecruitingPhase 3
Ketamine mist for depression
This trial tests if a ketamine mist you breathe in can help treat moderate to severe depression. It is for adults who are not helped enough by other treatments.
Brooklyn, New YorkAges 18–88 - NCT06756490RecruitingPhase 1
Study of HY-2003 for double chin reduction
This study tests a new medicine called HY-2003 to reduce extra fat under the chin (double chin). It is for adults who have moderate to severe submental fat and want to see if injections can help.
Beijing, Beijing MunicipalityAges 18–65 - NCT06754891RecruitingPhase 1
A study of TQH3906 for moderate to severe inflammatory bowel disease
This trial tests a new medicine (TQH3906) for people with moderate to severe ulcerative colitis or Crohn's disease that hasn't improved with other treatments. The goal is to see if it can help control inflammation in the gut.
Bengbu, AnhuiAges 18–75 - NCT06726096Enrolling by invitationPhase 3
Trial of VDJ001 for moderate to severe rheumatoid arthritis
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
Beijing, Beijing MunicipalityAges 18–75 - NCT06721962RecruitingPhase 1/Phase 2
Testing an experimental treatment for moderate to severe Crohn's disease
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Scottsdale, ArizonaAges 18–65 - NCT06716814RecruitingPhase 3
Continuing efanesoctocog alfa after earlier trial
This study provides continued access to the clotting factor treatment efanesoctocog alfa for people who have already been getting it in a previous trial. It helps ensure you can keep using the medicine if it is working for you.
PlovdivAges 6 years+ - NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06711146RecruitingEarly Phase 1
CAR T-cell therapy for active lupus
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18 years+ - NCT06682169RecruitingPhase 3
New pill for chronic graft-versus-host disease after other treatments fail
This trial tests a new pill called rovadicitinib for chronic GVHD that has not improved after 2 to 5 other treatments. It compares the new drug to one chosen by your doctor from a list of approved options.
Hefei, AnhuiAges 18–70 - NCT06390462Recruiting
Counseling for teens in school-based primary care
This study tests a brief counseling approach called Interpersonal Counseling for Adolescents (IPC-A) in school settings. It aims to help teens with emotional or social challenges before they become more serious, and it's designed for those who aren't already in mental health treatment.
HämeenlinnaAges 13–16 - NCT06651970RecruitingPhase 4
Acalabrutinib for chronic lymphocytic leukemia with heart problems
This trial tests a targeted therapy called acalabrutinib (a pill) against other standard treatments for chronic lymphocytic leukemia (CLL) in people who also have heart conditions. The goal is to see if acalabrutinib is a safer or more effective option for this group.
Charlotte, North CarolinaAges 18–130 - NCT06651177RecruitingPhase 2
Tirzepatide with buprenorphine for opioid use disorder
This study tests whether adding tirzepatide, a medication used for weight and blood sugar, to buprenorphine treatment helps people with opioid use disorder. It aims to see if the combination improves outcomes compared to buprenorphine alone.
Jacksonville, FloridaAges 18 years+ - NCT06617325RecruitingPhase 3
New drug for moderate to severe lupus
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Avondale, ArizonaAges 16 years+ - NCT06593392RecruitingPhase 2
Safety of difelikefalin for itching in teens on dialysis
This trial tests a drug called difelikefalin to see if it safely reduces moderate-to-severe itching in teenagers who are on hemodialysis. Itching is common in kidney disease, and this study aims to find a new treatment option.
ChengduAges 12–18 - NCT06591468Enrolling by invitationPhase 2/Phase 3
Prednisone Plus Ursodeoxycholic Acid for PBC Patients
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
Guangzhou, GuangdongAges 18–75 - NCT06239311RecruitingPhase 3
Methotrexate vs placebo for adults with eczema
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Prague, Praha 1Ages 18 years+
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.